antibodies Archives
James Crowe’s antibody research lands American Society for Microbiology Award
Sep. 13, 2023—Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.
VUMC, Oxford team develops ‘blueprint’ to block lethal virus
Jun. 22, 2023—Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.
Scientists resurrect a ‘dead’ antibody to study protein
Mar. 16, 2023—Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.
Discovery of “cross-reactive” antibodies could aid treatment of viral co-infections
Feb. 2, 2023— by Bill Snyder More than a million people in the United States are living with HIV, the virus that causes AIDS. One-fifth of them have been co-infected by the hepatitis C virus (HCV), which attacks the liver. Curative drugs for HCV are available, but many people don’t know they’ve been infected. And if they...
Novel lung cancer biomarker
Jan. 9, 2023—Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.
Rheumatoid arthritis and heart disease: a common path
Aug. 25, 2022—An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.
Grant set to support Georgiev’s research to identify new antibodies
Mar. 24, 2022—Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.
Technique hastens COVID-19 antibody discovery
Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
Omicron evades some but not all monoclonal antibodies: study
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...